| Collaborations |
|
Gilead Sciences, Inc.
|
|
PanVera LLC
|
|
Pharmagene Laboratories Limited
|
|
Johnson & Johnson
|
|
Amersham Biosciences
|
|
Lexicon Genetics Incorporated
|
|
Athersys, Inc.
Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.
|
|
Merck & Co., Inc.
Diabetes
|
|
Affinimark Technologies Inc.
|
|
GlaxoSmithKline (North Carolina)
|
|
Medarex, Inc.
|
|
Gilead Sciences, Inc. (Durham, NC)
|
|
Phyton Biotech, Inc.
- Cancer
|
|
Gilead Sciences, Inc. (Seattle, WA)
|